Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06469307 · ClinicalTrials.gov registry record · NA
Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
A NA study of Leukemia and Blood Cancer, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06469307: Recruiting NA study of Leukemia and Blood Cancer, sponsored by Dana-Farber Cancer Institute.
NCT06469307 is a NA study of Leukemia and Blood Cancer that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 40 participants, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06469307, a NA study of Leukemia and Blood Cancer, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to enhance inclusion and diversity in clinical trial enrollment by training participants to perform and provide feedback through a community-based protocol review process, called DIVERSE.
Primary Outcome
Feasibility is defined as the proportion of eligible protocols that have completed the DIVERSE review process. The target is a review completion of ≥ 60% of eligible protocols.
Conditions Studied
Interventions
- OTHER DIVERSE Review Process
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-12-09 |
| Est. Completion | 2027-06-30 |
| Phase | NA |
What NCT06469307 shows while recruiting
NCT06469307 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Leukemia appearing as the primary indexed condition, and to 1 intervention - of which DIVERSE Review Process is the first listed.
NCT06469307 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06469307 about?
NCT06469307 is a clinical study titled "Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)". The purpose of this research study is to enhance inclusion and diversity in clinical trial enrollment by training participants to perform and provide feedback through a community-based protocol review process, called DIVERSE.
What is the current status of trial NCT06469307?
This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2024-12-09. Estimated completion is 2027-06-30.
What conditions does trial NCT06469307 study?
This clinical trial studies the following conditions: Leukemia, Blood Cancer.
What interventions are being tested in trial NCT06469307?
The interventions under investigation include: DIVERSE Review Process (OTHER).
Who is sponsoring clinical trial NCT06469307?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06469307 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06469307's enrollment target sits among peer trials
40 130th of 233 higher than 95 of 233 other Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
RECRUITING · NA
-
Spiritual Care Intervention in Adult Patients Diagnosed With Acute Leukemia
RECRUITING · NA
-
I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients
RECRUITING · NA
-
HEME Home Transfusion Program
RECRUITING · NA
-
Effects of Using a Storybook, to Explain Leukemia to Children Versus the Standard Child Life Intervention, on Parental Stress.
RECRUITING · NA
-
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
- NCT02106988 · 40 participants · Phase 2
Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI